Rh3R Attenuates RANKL‐Induced Osteoclast Differentiation and F‐Actin Ring Formation via the Suppression of c‐Fos/NFATc1 Signaling in Primary Murine Cells
Journal of Cellular Physiology · 2026-04 · 241 (4)
DOI: 10.1002/jcp.70174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Physiology, online erschienen am 15.04.2026. Verfasst von Hyung-Mun Yun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Pathology, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Cell Differentiation, Osteoclasts, RANK Ligand, Proto-Oncogene Proteins c-fos. Die Arbeit nennt 50 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT).
Abstract (Originalsprache)
The homeostatic balance of bone remodeling is governed by the precise coordination between bone‐forming osteoblasts and bone‐resorbing osteoclasts. In this study, we investigated the anti‐resorptive properties of rhamnocitrin‐3‐rhamnoside (Rh3R), a flavonoid isolated from Loranthus tanakae , using primary bone marrow‐derived macrophages (BMMs) and calvaria‐derived osteogenic progenitor cells (COCs) to ensure biological relevance. Our findings demonstrate that Rh3R potently inhibits the RANKL‐induced differentiation of BMMs into TRAP‐positive multinucleated osteoclasts in a dose‐dependent manner, without inducing cytotoxicity. Mechanistically, Rh3R effectively attenuates RANKL‐induced downstream signaling cascades, as evidenced by the attenuated phosphorylation of MAPKs (ERK1/2, JNK, p38), AKT, and IκB. This signaling blockade subsequently suppresses the induction of the master transcription factors, c‐Fos and NFATc1. Furthermore, Rh3R impairs the functional resorptive capacity of mature osteoclasts by destabilizing F‐actin‐rich ring structures accompanied by decreased integrin β3 expression, thereby preventing the formation of a functional sealing zone. The inhibitory effect of Rh3R on bone‐degrading activity was further confirmed by a significant reduction in the total area of resorption pits on bone slices. Notably, Rh3R exhibits a lineage‐specific inhibitory effect, showing no adverse influence on osteoblastogenesis or the mineralizing capacity of primary osteogenic cells. Furthermore, the effect of Rh3R was consistently maintained in a co‐culture system of primary osteoblasts and BMMs. Collectively, these in vitro findings identify Rh3R as a bioactive modulator of osteoclast differentiation and function via suppression of RANKL‐induced downstream signaling, warranting future in vivo and pharmacological studies to evaluate efficacy, exposure, and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Pathology, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea.
- National Institute for Korean Medicine Development, Gyeongsan, Republic of Korea.
- Honam Regional Center, Korea Basic Science Institute, Gwangju, Republic of Korea.
Förderung
- National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
Zitieren
APA
Yun, H. M., Kim, S. H., Lee, J., & Park, K. R. (2026). Rh3R Attenuates RANKL‐Induced Osteoclast Differentiation and F‐Actin Ring Formation via the Suppression of c‐Fos/NFATc1 Signaling in Primary Murine Cells. Journal of Cellular Physiology, 241(4). https://doi.org/10.1002/jcp.70174
Vancouver
Yun HM, Kim SH, Lee J, Park KR. Rh3R Attenuates RANKL‐Induced Osteoclast Differentiation and F‐Actin Ring Formation via the Suppression of c‐Fos/NFATc1 Signaling in Primary Murine Cells. Journal of Cellular Physiology. 2026;241(4). doi:10.1002/jcp.70174
BibTeX
@article{Yun2026,
author = {Yun, Hyung-Mun and Kim, Soo Hyun and Lee, Joonyeop and Park, Kyung-Ran},
title = {Rh3R Attenuates RANKL‐Induced Osteoclast Differentiation and F‐Actin Ring Formation via the Suppression of c‐Fos/NFATc1 Signaling in Primary Murine Cells},
journal = {Journal of Cellular Physiology},
year = {2026},
volume = {241},
number = {4},
doi = {10.1002/jcp.70174}
}
EUVIMED